Theravance (TBPH) Director Dean J. Mitchell Disposes 232,489 Shares in Merger

What Happened

• Dean J. Mitchell, a director of Theravance Biopharma (TBPH), had a total of 232,489 ordinary shares and equity awards disposed/converted on September 23, 2026 as part of the company’s merger into Zymeworks. Each ordinary share was converted into $17.00 in cash and one contingent value right (CVR). The cash component equals approximately $3,952,313. In the filing, many items are marked as "derivative"—these were restricted stock units and/or options that were cancelled and converted under the merger terms.

Key Details

• Transaction date: September 23, 2026. Form 4 filed: September 24, 2026 (filed promptly the next day).
• Per-share cash consideration: $17.00; estimated cash received: $3,952,313; plus one CVR per share (non-tradeable, contingent cash right).
• Total shares/award units converted: 232,489 (sum of listed dispositions).
• Shares owned after transaction: reporting person no longer holds Theravance ordinary shares; instead received cash and CVRs per the merger.
• Footnotes: Merger Agreement dated June 28, 2026 converted ordinary shares to cash + CVRs (F1). Outstanding RSUs were cashed out similarly (F2). Outstanding options were cancelled/converted to cash equal to the excess of $17 over the exercise price times underlying shares, plus a CVR; options with exercise price ≥ $17 were cancelled for no consideration (F3).
• Transaction code: D (Disposition to issuer — conversion/cancellation in connection with the merger), not an open-market sale.

Context

• A "Disposition to issuer" here reflects the merger mechanics: shareholders and holders of RSUs/options received the merger consideration rather than selling shares on the open market. CVRs are contingent, non-tradeable rights that could pay additional cash only if specified post-merger commercial milestones are met. This is a routine outcome of an acquisition and should be interpreted as merger consideration rather than a voluntary insider sell-off.